Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study aims to investigate the effects of 24-hour acute sleep deprivation on plasma Alzheimer's disease biomarkers and multi-omics in individuals with different APOE genotypes, to elucidate the potential role of acute sleep deprivation in AD risk.
This is a randomized controlled trial designed to enroll 60 healthy volunteers. Stratified randomization will be used, with three strata defined by APOE genotype (APOE ε3/3, APOE ε4 carriers, and APOE ε2 carriers) in a 1:1:1 ratio. Within each stratum, participants will be randomly assigned in a 1:1 ratio to either the acute sleep-deprivation group or the non-acute sleep-deprivation group. The intervention will consist of 24 hours of acute sleep deprivation. The primary outcome measure is the change from baseline in plasma Aβ42 on the first day after randomization.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Sleep Deprivation | Experimental | 24 hours of sleep deprivation |
|
| Control | No Intervention | 24 hours of a normal work-rest schedule |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Sleep Deprivation | Behavioral | Sleep deprivation for up to 24 hours with no naps or other sleep periods |
|
| Measure | Description | Time Frame |
|---|---|---|
| Plasma Aβ42 levels | 1 day after randomization |
| Measure | Description | Time Frame |
|---|---|---|
| Plasma Aβ40 levels | 1 day after randomization | |
| Plasma t-tau levels | 1 day after randomization | |
| Plasma p-tau181 levels |
| Measure | Description | Time Frame |
|---|---|---|
| PET/MRI | Assessed using Positron Emission Tomography/Magnetic Resonance Imaging(PET/MRI) | 1 day after randomization |
| Proteomics | The plasma proteomics will be determined by Liquid Chromatography - MassSpectrometry |
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Guangdong Provincial Hospital of Chinese Medicine | Recruiting | Guangzhou | Guangdong | China |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D012892 | Sleep Deprivation |
| ID | Term |
|---|---|
| D020920 | Dyssomnias |
| D012893 | Sleep Wake Disorders |
| D009422 | Nervous System Diseases |
| D009461 | Neurologic Manifestations |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| 1 day after randomization |
| Plasma p-tau217 levels | 1 day after randomization |
| Plasma NfL levels | 1 day after randomization |
| Plasma GFAP levels | 1 day after randomization |
| Plasma Aβ42/Aβ40 levels | 1 day after randomization |
| Plasma t-tau/Aβ42 levels | 1 day after randomization |
| Plasma p-tau181/Aβ42 levels | 1 day after randomization |
| Plasma p-tau217/Aβ42 levels | 1 day after randomization |
| Fatigue Scale-14 | The Fatigue Scale-14 has a minimum score of 0 and a maximum score of 33; higher scores indicate greater fatigue severity. | 1 day after randomization |
| Positive and Negative Affect Schedule | The Positive and Negative Affect Schedule comprises two subscales: Positive Affect and Negative Affect. Each subscale ranges from 10 to 50, with higher scores indicating greater accumulation of the corresponding affect. | 1 day after randomization |
| N-back tasks | N-back test, participants are required to identify target digits that match the stimuli presented N steps earlier on the screen | 1 day after randomization |
| 1 day after randomization |
| Metabolomics | The plasma metabolomics will be determined by Liquid Chromatography - MassSpectrometry | 1 day after randomization |
| D012816 |
| Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D001523 | Mental Disorders |